Incidence, clinical and biological associations of anti-ETN antibodies
| Disease | Detection method | Patients (n) | ETN dosage | Period (weeks) | ADAb (%) | Association with serum trough ETN level | Association with clinical response | Association with AEs | Association with MTX | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | ELISA | 549 | 25 mg ×2/w | 193 | 5 | NR | No | No | NR | Klareskog et al117 |
| RIA, bridging ELISA and IgG4-ABT | 292 | 50 mg s.c./w or 25 mg×2/w | 26 | 0 | NR | NR | NR | NR | Jamnitski et al63 | |
| RIA | 40 | 25 mg s.c. ×2/w | 32 | 0 | NR | NR | NR | NR | Hoshino et al70 | |
| ELISA | 420 | 50 mg s.c./w | 16 | 3 | NR | No | NR | NR | Keystone et al9 | |
| ELISA | 214 | 50 mg s.c./w | 28 | 5.6 | NR | No | No | NR | Dore et al118 | |
| Ankylosing spondylitis | RIA | 53 | 25 mg ×2/w | 26 | 0 | NR | NR | NR | NR | de Vries et al119 |
| Psoriatic arthritis | NR | 205 | 25 mg ×2/w | 24 | 0 | NR | NR | NR | NR | Mease et al15 |
| Psoriasis | ELISA | 618 | 50 mg ×2/w | 12 | 1.5 | NR | No | No | NR | Tyring et al120 |
| ELISA | 583 | 25 or 50 mg ×2/w and then 25 mg ×2/w | 12 | 1.1 | NR | No | No | NR | Papp et al19 | |
| 24 | 1.6 | |||||||||
| ELISA | 652 | 25 mg ×1 or 2/w, or 50 mg ×2/w | 24 | 1.6 | NR | No | No | NR | Leonardi et al121 | |
| ELISA | 591 | 50 mg ×2/w | 12 | 18.3 | NR | No | No | NR | Tyring et al122 |
ADAb, antidrug antibodies; AEs, adverse events; ETN, etanercept; IgG4-ABT, immunoglobulin G4-antigen binding test; MTX, methotrexate; NR, not reported; RIA, radioimmunoassay; s.c., subcutaneous; w, week.